2024
Leveraging error-prone algorithm-derived phenotypes: Enhancing association studies for risk factors in EHR data
Lu Y, Tong J, Chubak J, Lumley T, Hubbard R, Xu H, Chen Y. Leveraging error-prone algorithm-derived phenotypes: Enhancing association studies for risk factors in EHR data. Journal Of Biomedical Informatics 2024, 157: 104690. PMID: 39004110, DOI: 10.1016/j.jbi.2024.104690.Peer-Reviewed Original ResearchElectronic health recordsElectronic health record dataKaiser Permanente WashingtonEHR-derived phenotypesAssociation studiesHealth recordsColon cancer recurrencePhenotyping errorsComputable phenotypeRisk factorsCancer recurrenceMultiple phenotypesReduce biasImprove estimation accuracySimulation studyBias reductionKaiserReduction of biasBiasEstimation accuracyAssociationStudyOutcomesRiskEstimation efficiency
2023
Systematic design and data-driven evaluation of social determinants of health ontology (SDoHO).
Dang Y, Li F, Hu X, Keloth V, Zhang M, Fu S, Amith M, Fan J, Du J, Yu E, Liu H, Jiang X, Xu H, Tao C. Systematic design and data-driven evaluation of social determinants of health ontology (SDoHO). Journal Of The American Medical Informatics Association 2023, 30: 1465-1473. PMID: 37301740, PMCID: PMC10436148, DOI: 10.1093/jamia/ocad096.Peer-Reviewed Original Research
2012
Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
Schildcrout J, Denny J, Bowton E, Gregg W, Pulley J, Basford M, Cowan J, Xu H, Ramirez A, Crawford D, Ritchie M, Peterson J, Masys D, Wilke R, Roden D. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clinical Pharmacology & Therapeutics 2012, 92: 235-242. PMID: 22739144, PMCID: PMC3785311, DOI: 10.1038/clpt.2012.66.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterAdverse eventsPreemptive genotypingPotential adverse eventsUniversity Medical CenterHome patientsPharmacogenetic associationsMedical CenterVariant allelesMedicationsDrug outcomesPatient safetyDrug decision makingRelevant genetic variantsRoutine integrationTarget drugsGenetic variantsOutcomesFrequency of opportunitiesGenotypingSafetyPrescribingPatientsCohortPharmacogenetics